TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cardiovascular Fitness (Arm Cycle Ergometry VO2 Peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in brain mechanical properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: urogynecologic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: digestive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient reported global symptom improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Discharged Opioid-Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the accuracy of risk perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PCR-corrected and parasitological response (ACPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease free Survival
Endpoint domain: Mortality/survival
Primary endpoint: percent of patients with a positive diagnosis of malignancy
Endpoint domain: Mortality/survival
Primary endpoint: percent of patients with inadequate samples
Endpoint domain: Adverse events/effects
Primary endpoint: GNRI mean-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet Engraftment Greater Than 50K/ul
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Consumption of propofol and opioid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Tremor Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Assessment of changes in the pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of changes in the depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Assessment of changes in the Waist and Hip circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transfusion Power Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient recruitment success
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient retention success
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients expressing Neurotensin receptor (NTSR1) in their tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Local Relapse-free Survival (LRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Ability to measure mGluR1 in brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of CSF-leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Phototherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Phototherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Skin Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG signal recording and Respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic and local reactions after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change in psoriasis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FDG uptake measured by standardized uptake value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tpeak-end interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in Hamilton Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in Motivation and Pleasure Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Re-infection with a non-viral sexually transmitted infection
Endpoint domain: Adverse events/effects
Primary endpoint: Mu opioid receptor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score on a grading scale at post treatment visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean of the Ratios Between Infant and Maternal Antibody Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with major cardiovascular adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive Assessments
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Supplemental Oxygen Free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transseptal Access Procedure Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to development of blood stage parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Migraine-related disability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Time to Target Eugonadal Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to Steady State (SS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gel Drying Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure or Blockage of the Stent (Occlusion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocyte subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of units of blood products transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Symptoms of angina pectoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete absorption of subretinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Event-free Survival at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Autism Diagnostic Observation Schedule (ADOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Test of Young Adult Social Skills Knowledge (TYASSK)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Korean Version of the Social Skills Rating System (K-SSRS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change From Baseline in Social Responsiveness Scale-2 (SRS-2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional Respiratory Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of centers satisfying structure criteria
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients complying with HD PPP process of care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with adequate HD measured by Kt/V
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Urine Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cmax and AUC for E1, E2, E1S, and L-5-methyl-THF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Superiority of IM olanzapine depot dosages compared with placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in frequency of bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Percentage of Time With CPAP Usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Systemic Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Ocular Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Achieved Greater Than or Equal to (>=) 10 Millimeter (mm) Schirmer Wetting Score Without Anesthesia at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Worsening in TUG Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete motor block regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apixaban concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in strength test (Dynamometer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Improvement Scale (CGIS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 5-item Work and Social Adjustment Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of patients in complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time usage per day on approval and handling alerts
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Alert-rate
Endpoint domain: Adverse events/effects
Primary endpoint: Cold-induced thermogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Beta-Amyloid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hopkins Verbal Learning Test (HVLT) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Movement Disorder Society--Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: family support
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Stable device placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Residual jet flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change in SF-36 V2 Physical Component Summary Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Analgesic effects of morphine and methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-protein D Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Pneumococcal Histidine Triad D Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-pneumolysin Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentrations for Serum Protein-D Enzymatic Inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With PD Enzymatic Inhibition Concentration Greater Than or Equal to (≥) 17.8%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Objective Response (Confirmed, Complete and Partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Pharmacokinetic (PK) variables for tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough concentration (Ctrough) for isavuconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of PK variables for isavuconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Half-emptying Time (T1/2) of Gastric Solids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acceptability - Module Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Navigator Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resistance to tearing of orthodontic brackets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment, lower extremity subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lactate dehydrogenase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: α-feto protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: β human Chorionic Gonadotropin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: carcinoembryonic antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bone health (DXA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cognitive function 1 (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: cortical bone tissue levels of pentosidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cortical bone tissue levels of pyridinoline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cortical bone tissue levels of matrix-bound water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to be symptoms free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of SARS-CoV2 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: implants survival
Endpoint domain: Mortality/survival
Primary endpoint: Transverse glottic diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted Mean Change From Baseline in Log Transformed C - Reactive Protein (CRP) at Day 84
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Alkaline Phosphatase, Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST) at Day 84
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Total Bilirubin, Creatinine, BUN, Phosphorus, Calcium, and Glucose at Day 84
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time expenditure of IFC with concomitant angiography
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Morbidity due to improved WASH behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of wild-type transthyretin cardiac amyloidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Delayed Bleeding Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tumor Specific Immunity Enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bacteriological efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Ketamine metabolism and clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol screening rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Observed Maximum Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve (AUC)-28 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Intraoperative Opioid (Fentanyl) Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PACU PONV rate and severity
Endpoint domain: Adverse events/effects
Primary endpoint: Time for caregivers to find a resident who falls at night
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of sedation use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical intraepithelial neoplasia grade 3 (CIN3) or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: post-hernioplasty acute pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Downtitration of Loop Diuretics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of deferasirox
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in liver histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of COVID-19 complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in scores on Caregiver Distress (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in scores on Caregiver Burden (ZBI-12)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in K6 total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients with drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of CVVH sessions ended prematurely
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Taken to Perform the Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Immune Responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: New onset diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in clinical picture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engraftment of Donor B-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in number of glaucoma medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in HAMD-17 Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Serum Glucose Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reactive Hypoglycemia Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Heavy Drinking Days (HDD%)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent of Drinking Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of recovery at Post operative day 1 (POD1)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Alpha, Theta, and Slow-Delta Wave Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional status by Karnofsky and ECOG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QOL) by SF-12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cognitive status by Short Orientation Concentration Memory Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Removal rate of 2-microglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety & Tolerability of Derma Vax
Endpoint domain: Adverse events/effects
Primary endpoint: VAS with/without EMLA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Hyperactive-Impulsive subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum/Urinary monocyte chemoattractant protein-1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: brain inflammation assessed by [18F]-DPA714, Standard Uptake Value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding Index (BOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral Inflammatory Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient related tennis elbow evaluation pain scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Patient related tennis elbow evaluation functional disability scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency of acute exacerbations of Chronic Obstructive Pulmonary Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severity of acute exacerbation of Chronic Obstructive Pulmonary Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Haemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood Levels of Calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood Levels of Phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood Levels of Intact Parathyroid Hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical Depression Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing